TrialInternational journal of clinical oncology2019

Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).

Nobuaki Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.